Skip to content

A clinical study to evaluate the safety and theraputic effect of regulatory T cells injection in treating systemic lupus erythematosus

A clinical study to evaluate the safety and theraputic effect of regulatory T cells injection in treating systemic lupus erythematosus

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800018050
Enrollment
Unknown
Registered
2018-08-28
Start date
2018-10-01
Completion date
Unknown
Last updated
2018-09-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Systemic Lupus Erythematosus

Interventions

case series:Regulatory T cells injection

Sponsors

Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Diagnosis of systemic lupus erythematosus comply with the 1997 SLE classification diagnostic criteria of the American Society of Rheumatology; 2. Aged 16 to 70 years old men and women; 3. Prednisone=10mg/d, CTX cumulative use of 6-8g is invalid, other immunosuppressants(Cyclosporin A, Azathioprine,Mycophenolate mofetil,et al) treat for 3 monthes are invalid; 4. The patients have clinical manifestation of different degrees fever, fatigue, alopecia, joint pain, facial redness, reynolds phenomenon, proteinuria respectively; 5. Normal function of important organs; 6. Signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Systemic lupus erythematosus is associated with serious complications of important organ failure; 2. Unable to produce T cell vaccine; 3. Peripheral blood leukocyte and(or)platelet are below the lower limit value of normal reference value; 4. Malignant tumor; 5. The history of organ transplantation; 6. Acquired and congenital immunodeficiency disease; 7. A history of allergies; 8. Women of pregnancy or lactation; 9. Participating in other clinical trials of drugs in the latest month; 10. There are serious diseases that endanger patients' safety or affect patients' completion of this study.

Design outcomes

Primary

MeasureTime frame
SLEDAI score;Leucocyte count;PLT Count;ALB;Cr;U- Pro;ANA;hs- CRP;Treg;IFN-?;dsDNA antibody;Sm antibody;ENA;AHA;ANCA;aCL;Mixed lymphocyte reaction;

Secondary

MeasureTime frame
C3;C4;IL-10;

Countries

China

Contacts

Public ContactZhao Zhenlin

Shenzhen Ruipuxun Academy for Stem Cell & Regenerative Medicine

zhaozl2006@163.com+86 13828895409

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026